Industry Roundup: FDA Investigation Prompts Criminal Charges Against Supplement Marketer

Watson opens supplement ingredient database; FTC shuts down melanoma app marketer; Amway’s Nutrilite wins halal award; more news in brief.

The operator of Floyd Nutrition LLC in Harrisburg, Pa., enters a plea agreement with the Department of Justice following an FDA investigation that determined the firm imported drug-spiked products marketed as weight loss supplements. The U.S. Attorney’s Office of the Middle District of Pennsylvania said on April 15 a criminal information was filed in U.S. District Court in Harrisburg charging Floyd Nutrition owner Cheryl Floyd with introducing misbranded drugs into interstate commerce and money laundering. Floyd Nutrition between July 2010 and July 2014 allegedly marketed weight loss products containing sibutramine, a prescription drug removed from the market in 2010, and phenolphthalein, previously available as an OTC stimulant laxative ingredient until FDA in 1999 reclassified it as not generally safe because it posed a carcinogenic risk, according to DoJ. After FDA detained shipments of the products coming from China intended for Floyd’s business, federal officials in July 2014 seized from Floyd Nutrition products sold online under brands including “Slim Trim U,” “ZXT Slim Bee Pollen” and “Natural Body Solutions.” The plea agreement, which includes forfeiting assets and properties and suggests that Floyd likely will be sentenced to supervised probation, is subject to the approval of the district court. In addition to FDA’s Office of Criminal Investigations, the case was investigated by the Internal Revenue Service Criminal Investigations and the Dauphin County Drug Task Force.

The Nutri-Knowledge database allows consumers as well as manufacturers and marketers to search vitamins, minerals, botanicals and other macro- and micronutrients quickly and easily, says dietary supplement ingredient developer Watson Inc

More from United States

New Guidance Suggests SubQ Keytruda, Opdivo Formulations May Not Avoid Medicare Negotiations

 

New draft guidance on the third cycle of Medicare drug price negotiations goes against Merck and Keytruda’s expectations for their cancer drugs. The guidance also tackles Part B and renegotiated prices for the first time.

Mayne’s Nextstellis Promo Wrong To Suggest Better Safety Than Other Contraceptives, FDA Says

 
• By 

A professional slide deck for the drospirenone/estetrol oral contraceptive inappropriately suggests it is safer than other estrogen-containing products and understates risks, Office of Prescription Drug Promotion said in the first “untitled” letter issued since reductions-in-force.

US HHS Deputy Nominee Talks AI, Not FDA, In Confirmation Hearing

 

Silicon Valley investor Jim O’Neill’s Senate confirmation hearings showcased the unique background of someone with government and tech experience and avoided discussions of his past statements about lowering the bar for regulatory approval.

US FDA Waiting On Guidance Agenda Future As HHS Seeks Regulation Cuts

 

The FDA continues to wait for a decision on whether its priority guidances will be published as HHS asks the public for potential regulation cuts to fulfill President Trump’s executive order.

More from North America

US FDA Rare Disease Case Studies Provide Development Models For Sponsors

 

Sanofi’s Xenpozyme and Sentynyl’s Nulibry are the first two case studies the FDA is using to continue educating rare disease sponsors on best practices.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.